Deepen your insight into the #pharma and #biopharma field! 💊 Are you passionate about the (bio)pharmaceutical industry? Do you want to stay up-to-date with the latest topics, trends, and technologies driving the industry forward? 🧪 Sign up for The Medicine Maker's newsletter today: https://bit.ly/3Vu15lw Join our community of industry professionals and enthusiasts now! #PharmaceuticalIndustry #Biotechnology
About us
The Medicine Maker celebrates the people, processes and vision that bring new drugs and biologics to market. The development and manufacture of new drugs and biological medicines draws on the talent, passion and experience of a wide range of professionals. The goal of The Medicine Maker is to bring this group into the limelight and, in doing so, to integrate the entire process, from the registration of an Investigational New Drug (IND) or Biologics License Application (BLA) through to the market launch of new therapies, and beyond.
- Website
-
http://themedicinemaker.com/
External link for The Medicine Maker
- Industry
- Internet Publishing
- Company size
- 11-50 employees
- Headquarters
- Knutsford, England
- Type
- Public Company
- Founded
- 2014
- Specialties
- pharmaceutical , biopharmaceutical, bioprocess, upstream, downstream, formulation, drug delivery, and dosage form
Locations
-
Primary
Chelford Road
Knutsford, England WA16 8, GB
-
Texere Publishing Inc. 175 Varick Street
New York, New York NY 10014, US
Updates
-
“Bikini Medicine” is the mistaken belief that women’s health only differs from men’s in the parts of the body that a bikini would cover. We need to acknowledge that #diseases can affect men and women differently - and may require different #treatments. 💊🚺 👉 https://bit.ly/3Q1dviK
-
Ever wondered how clinical trials will evolve in the digital age and beyond? Bari Kowal, head of development operations and portfolio management at Regeneron, shares her thoughts and predictions. Read more here: https://bit.ly/4cc0mMG
Regeneron on the Digital Age of Clinical Trials
themedicinemaker.com
-
How much change can patients cope with when it comes to their #drugdelivery device? According to Alex Fong, Head of Insight at Owen Mumford Pharmaceutical Services, we need to step away from assumptions on device interchangeability and find out what patients really want. Read more here: https://bit.ly/3zjTTkA
Managing Change in Devices for Patients
themedicinemaker.com
-
Diseases can affect men and women differently. We must acknowledge and accept that – and then optimize #drugdevelopment accordingly 💬👇 https://bit.ly/3Q1dviK
Beyond ‘Bikini Medicine'
themedicinemaker.com
-
#Cryogenic freezing performed too fast can damage #biopharma products. What’s the best way forward? Brian Moloney, Director New Products & Innovation at Single Use Support, gives his view. ❄️ Read more here: https://bit.ly/3zhl0MR
Frozen Assets
themedicinemaker.com
-
Why Does IBD Present So Many Clinical Research Challenges? Deepika Khedekar, Associate Centralized Clinical Trial Lead, IQVIA, acknowledges the shortcomings in IBD-related clinical trials and reveals a potential holistic approach to overcoming them. 👉 https://bit.ly/3TZRylf
Charting the Future of IBD Trials
themedicinemaker.com
-
Ascidian Therapeutics CEO Michael Ehlers aims to utilize #RNA exon editing to end #StargardtDisease. Read more here 👉 https://bit.ly/4cKsTcv
Enter Exon Editing
themedicinemaker.com
-
#ReadoftheWeek Check out our recent interview with Claudia Zylberberg, Founder of Akron Bio and ISCT, International Society for Cell & Gene Therapy Presidential Nominee 💬 👉 https://bit.ly/4cVfzSK
-
Lipid nanoparticles are a cornerstone of #mRNA therapeutics. For manufacturing, will you choose stainless steel or single-use? https://bit.ly/3USUqlJ